Revelation Biosciences is focused on developing innovative therapies that harness the concept of trained immunity to enhance the body's innate immune response. Their lead product, Gemini, is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) designed for systemic administration. Gemini is being investigated for multiple indications, including the prevention and treatment of post-surgical infections, acute kidney injury, and chronic kidney disease. The company believes that Gemini's mechanism of action involves redirecting the immune response from a pro-inflammatory state to a protective anti-inflammatory state, which may help mitigate tissue damage and promote healing.

In addition to Gemini, Revelation is advancing specific programs such as GEM-AKI and GEM-CKD, targeting acute and chronic kidney diseases, respectively. Preclinical studies have shown promising results, indicating that systemic pretreatment with PHAD can significantly protect against acute kidney injury and may slow the progression of chronic kidney disease. Furthermore, the GEM-SSI program aims to prevent healthcare-associated bacterial infections by stimulating the immune system to better respond to pathogens. Overall, Revelation Biosciences is leveraging its scientific expertise to develop therapies that could significantly improve patient outcomes in various critical health conditions.

United States

We develop immunologic therapeutics and diagnostics designed to make the world a healthier place. $6.2 Million Public Offering on February 5, 2024. 

Revelation Biosciences

Company Details